Evolva enters partnership on active pharmaceutical ingredients
Partner to fully fund development of new production routes for a family of APIs
Advertisement
Evolva has entered into an agreement with a private US biotech venture to develop new production routes for a family of existing active pharmaceutical ingredients (“API”).
Evolva will be responsible for the development of the production routes, whilst the partner will be responsible for the registration and commercialisation of the resulting products. The partner’s management has many decades of experience in developing and commercialising pharmaceuticals.
The collaboration will both benefit from, and provide benefits to, some of Evolva’s existing product developments and follows Evolva’s strategy of monetising applications outside its focus areas with partners.
Evolva will receive a low single digit million US dollar sum over the next 12 months with later phases potentially increasing this to several tens of millions of dollars in R&D funding. Evolva also receives a 20% equity stake in the partner.
This partnership does not change the revenue guidance for 2016.
Other news from the department business & finance
These products might interest you
Tailor-made products for specific applications by IPC Process Center
Granulates and pellets - we develop and manufacture the perfect solution for you
Agglomeration of powders, pelletising of powders and fluids, coating with melts and polymers
Custom qPCR and dPCR primers and PCR assay development. by Microsynth
Assay Design, Validation and Analysis - Primers and Probes for qPCR and dPCR Applications
High-quality qPCR and dPCR probes, extensive experience in assay design, development and validation
